Onconaut Therapeutics was founded in 2022 based on groundbreaking research in Dr. Dan LaBarbera’s lab at the University of Colorado, Anschutz. The company is undertaking IND-enabling studies to facilitate first-in-human validation of promising drug leads against CHD1L.

CHD1L is over-expressed in multiple cancers, leading to aggressive tumor behavior and unfavorable patient outcomes. Leveraging a comprehensive understanding of this oncogene, Onconaut is developing small molecule drugs that effectively inhibit CHD1L, blocking the cancer's ability to progress, survive, and evade treatments.